Clinical management and algorithms in osteoporosis

Hospital Medicine

Volumn 64, Issue 9, 2003, Pages 512-516

  Bubbear, Judith ^a   Keen, Richard ^a,b  

^a ROYAL NATIONAL ORTHOPAEDIC HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; CALCITONIN; CALCITRIOL; CALCIUM; ETIDRONIC ACID; PAMIDRONIC ACID; PARATHYROID HORMONE; RALOXIFENE; RISEDRONIC ACID; STRONTIUM; TIBOLONE; VITAMIN D; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ALGORITHM; CLINICAL TRIAL; CONFERENCE PAPER; DIET; EXERCISE; FRACTURE; HIGH RISK POPULATION; HUMAN; META ANALYSIS; OSTEOPOROSIS; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; SMOKING CESSATION; DIET THERAPY; HORMONE SUBSTITUTION; KINESIOTHERAPY; PROTECTIVE EQUIPMENT; REVIEW; RISK ASSESSMENT; SMOKING;

ALGORITHMS; CALCIUM; DIPHOSPHONATES; EXERCISE THERAPY; FRACTURES, BONE; HORMONE REPLACEMENT THERAPY; HUMANS; OSTEOPOROSIS; PARATHYROID HORMONE; PROTECTIVE DEVICES; RISK ASSESSMENT; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SMOKING; VITAMIN D;

EID: 0141955072     PISSN: 14623935     EISSN: None     Source Type: Journal    
DOI: 10.12968/hosp.2003.64.9.2241     Document Type: Conference Paper

References (21)

1. Black DM, Thompson DE, Bauer DC et al (2000) fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial. J Clin Endocrinol Met 85: 4118-24
2. Chapuy MC, Arlot ME, Delmas PD, Meunier PJ (1994) Effect of calcium and cholecalciferol treatment for three years on hip fracture in elderly women. Br Med J 308: 1081-2
3. Cummings SR, Nevitt MC, Browner WS et al (1995) Risk factors for hip fracture in white women. N Engl J Med 332: 767-73
4. Department of Health (2001) National Service Framework for Older People. Department of Health, London (http://www.doh.gov.uk/nsf/olderpeople.htm)
5. Dolan P, Torgerson D (1998) The Cost of Treating Osteoporotic Fractures in the UK Female Population. Osteoporos Int 8: 611-7
6. Ettinger B, Black DM, Mitlak BH et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3 year randomized clinical trial. JAMA 282: 637-45
7. Harris ST, Watts NB, Genat HK et al (1999) Effects of rise-dronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 282: 1344-52
8. Kanis JA, Johnell O, Oden A, De Laet C, Jonsson B, Dawson A (2002) Ten-year risk of osteoporotic fracture and the effect of risk factors on screening strategies. Bone 30: 251-8
9. Law MR, Hackshaw AK (1997) A meta-analysis of cigarette smoking, bone mineral density and risk of hip fracture: recognition of a major effect. Br Med J 315: 841-6
10. Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fracture. Br Med J 312: 1254-9
11. McClung MR, Geusens P, Miller PD et al (2001) Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 344: 333-40
12. Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344: 1434-41
13. Reginster JY, Meunier PJ (2003) Strontium ranelate phase 2 dose-ranging studies: PREVOS and STRATOS studies. Osteoporos Int 14: S19-S24
14. Rossouw JE, Anderson GL, Prentice RL et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA 288: 321-33
15. Royal College of Physicans and Bone and Tooth Society (2000) Osteoporosis - Clinical Guidelines for Prevention and Treatment - Update on pharmacological interventions and an algorithm for management. Royal College of Phyisicans, London
16. Tonino RP, Meunier PJ, Emkey R et al (2000) Skeletal benefits of aledronate: 7 year treatment of postmenopausal osteoporotic women. J Clin Endocrinol Metab 85: 3109-15
17. Torgerson DJ, Bell-Syer SE (2001a) Hormone replacement therapy and prevention of vertebral fractures: a meta-analysis of randomized trials. BMC Musculoskelet Disord 2: 7
18. Torgerson DJ, Bell-Syer SE (2001b) Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA 285: 2891-7
19. Van Schoor NM, Deville WL, Bouter LM et al (2002) Acceptance and compliance with external hip protectors: a systemic review of the literature. Osteoporos Int 13: 917-24
20. Van Schoor NM, Asma G, Smit JH, Bouter LM, Lips P (2003) The Amsterdam Hip Protector Study: complaince and determinants of compliance. Osteoporos Int 14: 353-9
21. World Health Organization (1994) Assessment of Fracture Risk and its Application to Screening for Postmenopausal Osteoporosis. Technical Report Series. World Health Organization, Geneva